(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[(2S,3S)-2-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3-(pyrimidin-2-yloxy)-pyrrolidine-1-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835316

PubChem CID: 56670256

Max Phase: Preclinical

Molecular Formula: C29H41N7O11

Molecular Weight: 663.69

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CC[C@H](Oc2ncccn2)[C@H]1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI:  InChI=1S/C29H41N7O11/c1-13(2)21(32-15(5)37)25(42)33-16(11-19(38)39)24(41)35-22(14(3)4)27(44)36-10-7-18(46-29-30-8-6-9-31-29)23(36)26(43)34-17-12-20(40)47-28(17)45/h6,8-9,13-14,16-18,21-23,28,45H,7,10-12H2,1-5H3,(H,32,37)(H,33,42)(H,34,43)(H,35,41)(H,38,39)/t16-,17-,18-,21-,22-,23-,28?/m0/s1

Standard InChI Key:  KATUELUJWVLCGP-VUACEQFZSA-N

Molfile:  

     RDKit          2D

 47 49  0  0  0  0  0  0  0  0999 V2000
   29.5836  -13.1420    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.9103  -13.6179    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.1544  -14.4063    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.9800  -14.4203    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.2441  -13.6380    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.4574  -15.0925    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.1334  -13.3547    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.5997  -12.3179    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8477  -11.9742    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.1871  -10.6623    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8521  -11.1498    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.5224  -10.6694    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.2705   -9.8817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.4469   -9.8811    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0495  -10.6623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7608  -10.2501    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   20.3340  -10.2501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.0495  -11.4868    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.4762  -10.6623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1916  -10.2501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.4762  -11.4868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.7608  -11.8991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.1916  -11.8991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.9029  -10.6623    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   23.1916   -9.4256    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   24.6183  -10.2501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.3338  -10.6623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.6183   -9.4256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.3338  -11.4868    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.3338   -9.0133    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0499   -9.4267    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.3346   -8.1899    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.0450  -10.2501    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   26.7604  -10.6623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4717  -10.2501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7604  -11.4868    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.0450  -11.8991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4717  -11.8991    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.4717   -9.4256    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   28.1529  -12.4180    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   30.3033  -10.9235    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   31.0085  -10.4964    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.7271  -10.8974    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.4319  -10.4709    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.4151   -9.6457    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.6875   -9.2488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.9857   -9.6775    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
  9  8  1  0
 10 11  1  0
  1  2  1  0
  2  3  1  0
 15 16  1  0
 15 17  1  0
 15 18  2  0
 16 19  1  0
 19 20  1  0
 19 21  1  6
 21 22  1  0
 21 23  1  0
 20 24  1  0
 20 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  1  1
 27 29  2  0
 28 30  1  0
 30 31  1  0
 30 32  2  0
 27 33  1  0
 33 34  1  0
 34 35  1  0
 34 36  1  6
 36 37  1  0
 36 38  1  0
 35 10  1  0
 35 39  2  0
  3  4  1  0
  9 40  2  0
  4  5  1  0
 12 41  1  6
 11 12  1  0
 41 42  1  0
 12 13  1  0
 42 43  2  0
 13 14  1  0
 43 44  1  0
 14 10  1  0
 44 45  2  0
 11  9  1  1
 45 46  1  0
  1  5  1  0
 46 47  2  0
 47 42  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CASP3 Tchem Caspase-3 (3632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 663.69Molecular Weight (Monoisotopic): 663.2864AlogP: -2.16#Rotatable Bonds: 14
Polar Surface Area: 255.55Molecular Species: ACIDHBA: 12HBD: 6
#RO5 Violations: 3HBA (Lipinski): 18HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.26CX Basic pKa: 1.87CX LogP: -2.22CX LogD: -5.22
Aromatic Rings: 1Heavy Atoms: 47QED Weighted: 0.12Np Likeness Score: 0.16

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C..  (2011)  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.,  19  (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors.  2006-03-09  Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.  [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors.  2011-10-01  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.  [PMID:21903398]

Source